3 studies found for:    CLBH589BUS48T
Show Display Options
Rank Status Study
1 Completed Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Interventions: Drug: Panobinostat;   Drug: Bortezomib
2 Terminated ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Panobinostat (LBH589)
3 Active, not recruiting Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease
Condition: Graft-Versus-Host Disease
Intervention: Drug: Panobinostat (LBH589)

Indicates status has not been verified in more than two years